Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 3/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897077 | 0.85 | RIPK1 (0.38) | RIPK1ADORA3ADORA2AADORA1CCKBR | |
| SCHEMBL8274324 | 0.84 | POLB (0.36) | RIPK1ADORA3ADORA2AADORA1 | |
| SCHEMBL5396473 | 0.75 | RIPK1 (0.48) | RIPK1CCKBR | |
| SCHEMBL8274307 | 0.74 | DPP4 (0.41) | RIPK1 | |
| SCHEMBL4899283 | 0.74 | SCN9A (0.38) | RIPK1CCKBRCCKAR | |
| SCHEMBL8274755 | 0.74 | ADORA3 (0.41) | RIPK1ADORA3ADORA2AADORA1MEN1 | |
| Hydrochloric Acid SCHEMBL4889639 | 0.74 | DPP4 (0.41) | RIPK1 | |
| Hydrochloric Acid SCHEMBL4899317 | 0.72 | ADORA3 (0.40) | RIPK1ADORA3ADORA2AADORA1MEN1 | |
| Hydrochloric Acid SCHEMBL4892564 | 0.72 | ADORA3 (0.40) | RIPK1ADORA3ADORA2AADORA1MEN1 | |
| SCHEMBL19207718 | 0.72 | RIPK1 (0.48) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | RIPK1 3999/4885ADORA3 342/4885ADORA2A 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.